Clinical Trials Browser

OTHER × parsaclisib × Dermatologic × Clear all

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Phase 1 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic